Skip to main content

MediSapiens, Bayer Developing Platform for Cancer Genomic Data Analysis

NEW YORK (GenomeWeb News) – MediSapiens today announced that it and Bayer HealthCare Pharmaceuticals have reached an agreement to develop a platform for the analysis of cancer genomics data.

"Genomics data is increasingly used both in preclinical and clinical research, but lacks software tools that can be adapted to various research environments," Tommi Pisto, CEO of MediSapiens, said in a statement. "Our flexible platform and know-how in designing software for demanding bioinformatics environments will be tailored to meet the needs of oncology research at Bayer HealthCare Pharmaceuticals."

Financial and other terms were not disclosed.

MediSapiens is a startup bioinformatics firm based in Helsinki. It received $1 million in seed funding in the spring of 2010.

The Scan

WHO OKs Emergency Use of Sinopharm Vaccine

The World Health Organization has granted emergency approval for Sinopharm's SARS-CoV-2 vaccine, the Guardian reports.

Scientific Integrity Panel to Meet

According to the Associated Press, a new US scientific integrity panel is to meet later this week.

Trying in the Eye

NPR reports that a study of Editas Medicine's CRISPR therapy for Leber congenital amaurosis has begun.

PLOS Papers on Cerebellum Epigenetics, Copy Number Signature Tool, Acute Lung Injury Networks

In PLOS this week: epigenetics analysis of brain tissue, bioinformatics tool to find copy number signatures in cancer, and more.